Is lurbinectedin in trials beyond small cell lung cancer?
Lurbinectedin, approved as Zepzelca for metastatic small cell lung cancer (SCLC) after platinum-etoposide failure, is under study for other cancers. Ongoing trials explore its use alone or combined with immunotherapy and chemo in solid tumors.[1]
Trials targeting ovarian cancer
Phase II and III trials test lurbinectedin in platinum-resistant ovarian cancer, often with other agents like doxorubicin liposomal or pembrolizumab. A key example is NCT02448625, evaluating it post-platinum failure.[2][3]
Prostate cancer studies
NCT03994703 examines lurbinectedin plus olaparib in metastatic castration-resistant prostate cancer, focusing on DNA repair-deficient cases unresponsive to prior therapies.[4]
Trials in head and neck cancers
NCT03957590 investigates lurbinectedin with weekly paclitaxel in recurrent or metastatic head and neck squamous cell carcinoma, aiming to improve response rates after standard treatments fail.[5]
Mesothelioma and other thoracic cancers
Phase II trial NCT04169842 combines lurbinectedin with atezolizumab for malignant pleural mesothelioma. Separate studies look at it in thymic epithelial tumors.[6]
Pediatric and rare tumor applications
NCT04851119 tests lurbinectedin monotherapy in children and young adults with relapsed/refractory solid tumors or lymphomas, including Ewing sarcoma and osteosarcoma.[7]
How to track active trials
Search ClinicalTrials.gov for 'lurbinectedin' yields over 50 results, with statuses from recruiting to completed. Many focus on combinations to overcome resistance in relapsed settings.[8]
[1] FDA.gov - Zepzelca Approval Summary
[2] ClinicalTrials.gov - NCT02448625
[3] ClinicalTrials.gov - NCT04722647 (Phase III ovarian combo)
[4] ClinicalTrials.gov - NCT03994703
[5] ClinicalTrials.gov - NCT03957590
[6] ClinicalTrials.gov - NCT04169842
[7] ClinicalTrials.gov - NCT04851119
[8] ClinicalTrials.gov - Search 'lurbinectedin'